Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice.
Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, Liu M, Allbritton O, Woodruff A, Wu Q, D'Orvilliers A, Garnova E, Rafique A, Poueymirou W, Martin J, Huang T, Skokos D, Kantrowitz J, Popke J, Mohrs M, MacDonald D, Ioffe E, Olson W, Lowy I, Murphy A, Thurston G. Burova E, et al. Among authors: allbritton o. Mol Cancer Ther. 2017 May;16(5):861-870. doi: 10.1158/1535-7163.MCT-16-0665. Epub 2017 Mar 6. Mol Cancer Ther. 2017. PMID: 28265006
Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice.
Burova E, Hermann A, Dai J, Ullman E, Halasz G, Potocky T, Hong S, Liu M, Allbritton O, Woodruff A, Pei J, Rafique A, Poueymirou W, Martin J, MacDonald D, Olson WC, Murphy A, Ioffe E, Thurston G, Mohrs M. Burova E, et al. Among authors: allbritton o. Mol Cancer Ther. 2019 Nov;18(11):2051-2062. doi: 10.1158/1535-7163.MCT-18-1376. Epub 2019 Aug 8. Mol Cancer Ther. 2019. PMID: 31395688